VaxGen Gets OK to Test Anthrax Vaccine

VaxGen Inc., which is developing vaccines for AIDS and smallpox, said it won Food and Drug Administration approval to begin testing a treatment to prevent anthrax.

Testing for the anthrax vaccine on about 100 volunteers will begin in June, a company spokesman said.

Shares of Brisbane, Calif.-based VaxGen rose 20 cents to $3.34 on Nasdaq.

The vaccine will be tested at Houston's Baylor College of Medicine, Atlanta's Emory University, Baltimore's Johns Hopkins University and Saint Louis University Health Sciences Center.